NASDAQ$LFST
LifeStance Health Group Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
LifeStance Health Group Inc reported Q2 2025 revenue of $345.3 million with a net loss of $3.8 million.
LifeStance Health Group Inc delivered total revenue of $345.3 million for the three months ended June 30, 2025, reflecting 11% year-over-year growth driven by clinician expansion and increased patient visits. The company reported a net loss of $3.8 million and loss from operations of $3.0 million, with Center Margin reaching $108.4 million and Adjusted EBITDA of $34.0 million. Clinician headcount grew to 7,708, supporting 2.2 million visits in the quarter.
- Q2 2025 revenue grew 11% YoY to $345.3 million on 12% higher patient visits from organic clinician hiring.
- Net loss narrowed to $3.8 million from $23.3 million in Q2 2024, with loss from operations improving to $3.0 million.
- Center Margin expanded to $108.4 million and Adjusted EBITDA rose to $34.0 million, reflecting operating leverage.
- Cash and cash equivalents increased to $188.9 million at quarter end, supported by $61.3 million operating cash flow for the first half.
Headline financials
Revenue & EPS history
LifeStance · Revenue · Quarterly
$345M
Revenue by segment
LifeStance · $343M total across 3 segments · Q2 2025
- Commercial$312M—91.1%
- Government$17.8M—5.2%
- Self-pay$12.5M—3.7%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-4.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.2%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+24.6%
Q4 2023
Best reaction
-49.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +19.8% | +7.7% | +0.5% | |
| Q4 2025 | +4.3% | +0.0% | -11.5% | |
| Q3 2025 | -3.6% | +29.1% | +30.1% | |
| Q1 2025 | -16.0% | -10.7% | -10.8% | |
| Q4 2024 | +3.1% | +6.8% | -10.8% | |
| Q3 2024 | +3.2% | +3.8% | +2.9% | |
| Q2 2024 | +1.6% | +6.0% | +26.1% | |
| Q1 2024 | -1.7% | +5.9% | -19.1% | |
| Q4 2023 | +24.6% | +21.8% | -3.4% | |
| Q3 2023 | -9.4% | -8.9% | +7.9% | |
| Q2 2023 | -5.0% | -7.4% | -17.1% | |
| Q1 2023 | -1.4% | +1.1% | +1.7% | |
| Q4 2022 | +22.2% | +23.8% | +65.6% | |
| Q3 2022 | -30.4% | -15.9% | -23.0% | |
| Q2 2022 | +6.2% | +10.8% | +29.3% | |
| Q1 2022 | -13.9% | +0.4% | +10.1% | |
| Q4 2021 | -12.7% | -5.9% | +4.2% | |
| Q3 2021 | -27.3% | -22.8% | -29.1% | |
| Q2 2021 | -49.7% | -40.6% | -30.2% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro